- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.10. | Pfizer's RSV vaccine cleared by FDA for use in some younger adults | ||
| 23.10. | Merck acquires cancer drug startup; Elevidys ex-US sales rise | ||
| 23.10. | Amgen plans launch of Eylea biosimilar after court ruling | ||
| 22.10. | FDA names Tarver as new head of device center | ||
| 22.10. | Starboard makes case for change at Pfizer, citing research, M&A missteps | ||
| 22.10. | Editas, changing course again, looks to partner lead CRISPR therapy | ||
| 22.10. | Otsuka's startup bet pays off with kidney disease drug results | ||
| 22.10. | RNA editing: emerging from CRISPR's shadow | ||
| 21.10. | Sanofi moves ahead with CD&R deal for stake in consumer business | ||
| 21.10. | Oral version of Novo diabetes drug protects heart health in large study | ||
| 21.10. | Brain drug developer Seaport raises another $225M | ||
| 21.10. | PureTech thinks the "hub-and-spoke" startup model is still a good bet. If only investors agreed. | ||
| 21.10. | Pharmaceutical research on mRNA and CAR T-cell therapy in cancer: Pioneering the future of oncology | ||
| 21.10. | Harnessing the power of upstream platform integration to accelerate biopharma innovation | ||
| 18.10. | Merck antibody reduces RSV-related disease, hospitalizations in trial | ||
| 18.10. | Gilead withdraws Trodelvy in bladder cancer | ||
| 18.10. | CVS replaces CEO Karen Lynch with Caremark head | ||
| 18.10. | PTC rebuffed again by EMA; Novartis licenses China-based biotech's cancer drug | ||
| 17.10. | Sage to cut one-third of workforce, streamline drug pipeline | ||
| 17.10. | After rejections, AbbVie secures approval for Parkinson's drug | ||
| 17.10. | Sanofi, expanding in radiopharma, strikes a joint venture deal | ||
| 17.10. | Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe | ||
| 16.10. | Novocure wins FDA approval for electric field device in lung cancer | ||
| 16.10. | FDA puts Novavax flu vaccine trials on hold | ||
| 16.10. | Wave sees RNA editing validation in early trial results |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
